Medical Enterprises Europe B.V.   Report issue

For profit Phase 3
Founded: Amstelveen Netherlands (1994)
Status: No NME R&D (1994)

Organization Overview

First Clinical Trial
2002
NCT00384891
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2018

Timeline

NOW
  • Now

Alternative names

Medical Enterprises Ltd.

Active Ingredients

Drugs in Phase 3 Trials (2)

bacille calmette-guerin (2 trials)

mitomycin (mutamycin) (3 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Carcinoma (Phase 3)

Carcinoma in Situ (Phase 3)

Carcinoma, Papillary (Phase 3)

Fever (Phase 3)

Neoplasms (Phase 3)

Neoplasms by Site (Phase 3)

Urinary Bladder Diseases (Phase 3)

Urinary Bladder Neoplasms (Phase 3)

Urogenital Neoplasms (Phase 3)

Urologic Diseases (Phase 3)

Urologic Neoplasms (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 3
  • # of Trial APIs: 2